These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 17159338)
1. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone. Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150 [TBL] [Abstract][Full Text] [Related]
3. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Rodríguez JN; Martino ML; Diéguez JC; Prados D Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866 [TBL] [Abstract][Full Text] [Related]
4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570 [TBL] [Abstract][Full Text] [Related]
5. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916 [TBL] [Abstract][Full Text] [Related]
6. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS). Marques da Costa R Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Nowrousian MR Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333 [TBL] [Abstract][Full Text] [Related]
8. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Biggs JC; Atkinson KA; Booker V; Concannon A; Dart GW; Dodds A; Downs K; Szer J; Turner J; Worthington R Bone Marrow Transplant; 1995 Jan; 15(1):129-34. PubMed ID: 7742745 [TBL] [Abstract][Full Text] [Related]
10. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544 [TBL] [Abstract][Full Text] [Related]
11. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study]. Sinnassamy P; Andre JL; Treize G; Leroy B Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412 [TBL] [Abstract][Full Text] [Related]
12. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period]. Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Durmaz O; Demirkaya M; Sevinir B Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Hasselbalch HC; Clausen NT; Jensen BA Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186 [TBL] [Abstract][Full Text] [Related]
16. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Granell M; Vallansot R; Besses C; Montserrat E Br J Haematol; 2006 Jul; 134(2):184-6. PubMed ID: 16740139 [TBL] [Abstract][Full Text] [Related]
17. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function. Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results. Phair JP; Abels RI; McNeill MV; Sullivan DJ Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662 [TBL] [Abstract][Full Text] [Related]
19. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma]. Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713 [TBL] [Abstract][Full Text] [Related]